Organelle Specific Macrophage Engineered Vesicles Differentially Reprogram Macrophage Polarization.
cancer
exosome
immunomodulation
macrophages
vesicles
Journal
Advanced healthcare materials
ISSN: 2192-2659
Titre abrégé: Adv Healthc Mater
Pays: Germany
ID NLM: 101581613
Informations de publication
Date de publication:
06 Sep 2024
06 Sep 2024
Historique:
revised:
27
08
2024
received:
22
05
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
6
9
2024
Statut:
aheadofprint
Résumé
Tumor-associated macrophages (TAMs) represent the majority of the immune cells present in the tumor microenvironment. These macrophages exhibit an anti-inflammatory (M2)-like physiological state and execute immune-suppressive and tumor-supporting properties. With TAMs being plastic, there is a growing interest in reprogramming them toward a pro-inflammatory (M1)-like phenotype that exhibits anti-tumoral properties. Recent studies have demonstrated that both engineered vesicles derived from macrophages and endogenous extracellular vesicles produced by macrophages can be programmed to alter macrophage phenotype. Here it is demonstrated that pro-inflammatory macrophage-engineered subcellular vesicles (MEVs) have differential properties based on their organelle of origin. Endoplasmic reticulum specific MEVs (erMEVs) treated M2 macrophages exhibit enhanced pro-inflammatory cytokine production compared to plasma membrane specific MEVs (pmMEVs) treated M2 macrophages. In addition, under in vitro co-culture conditions, erMEVs elicit superior efficacy in suppressing the viability of cancer cells compared to the same concentration of pmMEVs. Furthermore, erMEVs and pmMEVs maintain differences in their membrane proteins, that regulate the repolarization efficacy of M2 macrophages toward an M1-like phenotype. In addition, The M2 to M1 repolarizing efficacy of MEVs can be altered by changing the activity of the membrane proteins present on erMEVs or pmMEVs.
Identifiants
pubmed: 39240019
doi: 10.1002/adhm.202401906
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2401906Subventions
Organisme : NIH HHS
ID : GM138837
Pays : United States
Organisme : NIH HHS
ID : GM138882
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35GM124977
Pays : United States
Informations de copyright
© 2024 Wiley‐VCH GmbH.
Références
a) A. J. Boutilier, S. F. Elsawa, Int. J. Mol. Sci. 2021, 22, 6995;
b) D. Schweer, A. McAtee, K. Neupane, C. Richards, F. Ueland, J. Kolesar, Cancers 2022, 14, 2220;
c) N. R. Anderson, N. G. Minutolo, S. Gill, M. Klichinsky, Cancer Res. 2021, 81, 1201.
a) A. Ozinsky, D. M. Underhill, J. D. Fontenot, A. M. Hajjar, K. D. Smith, C. B. Wilson, L. Schroeder, A. Aderem, Proc. Natl. Acad. Sci. USA 2000, 97, 13766;
b) P. Taylor, L. Martinez‐Pomares, M. Stacey, L. H‐H, Annu. Rev. Immunol. 2005, 23, 901;
c) T. H. Mogensen, Clin. Microbiol. Rev. 2009, 22, 240.
D. M. Mosser, J. P. Edwards, Nat. Rev. Immunol. 2008, 8, 958.
a) A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, M. Locati, Trends Immunol. 2004, 25, 677;
b) S. K. Biswas, A. Mantovani, Nat. Immunol. 2010, 11, 889;
c) A. Sica, V. Bronte, J. Clin. Invest. 2007, 117, 1155;
d) C. Guiducci, A. P. Vicari, S. Sangaletti, G. Trinchieri, M. P. Colombo, Cancer Res. 2005, 65, 3437;
e) D. F. Fiorentino, A. Zlotnik, T. R. Mosmann, M. Howard, A. O'Garra, J. Immunol. 1991, 147, 3815.
J. C. Zarif, R. S. Taichman, K. J. Pienta, Oncoimmunology 2014, 3, e941734.
M. Xiao, J. He, L. Yin, X. Chen, X. Zu, Y. Shen, Front. Immunol. 2021, 12, 799428.
a) Y. W. Choo, M. Kang, H. Y. Kim, J. Han, S. Kang, J.‐R. Lee, G.‐J. Jeong, S. P. Kwon, S. Y. Song, S. Go, M. Jung, J. Hong, B.‐S. Kim, ACS Nano 2018, 12, 8977;
b) F. Zhang, N. N. Parayath, C. I. Ene, S. B. Stephan, A. L. Koehne, M. E. Coon, E. C. Holland, M. T. Stephan, Nat. Commun. 2019, 10, 3974.
M. Liu, R. S. O'Connor, S. Trefely, K. Graham, N. W. Snyder, G. L. Beatty, Nat. Immunol. 2019, 20, 265.
E. Müller, P. F. Christopoulos, S. Halder, A. Lunde, K. Beraki, M. Speth, I. Øynebråten, A. Corthay, Front. Immunol. 2017, 8, 1383.
H. Sands, L. J. Gorey‐Feret, A. J. Cocuzza, F. W. Hobbs, D. Chidester, G. L. Trainor, Mol. Pharmacol. 1994, 45, 932.
N. Butowski, H. Colman, J. F. De Groot, A. M. Omuro, L. Nayak, P. Y. Wen, T. F. Cloughesy, A. Marimuthu, S. Haidar, A. Perry, J. Huse, J. Phillips, B. L. West, K. B. Nolop, H. H. Hsu, K. L. Ligon, A. M. Molinaro, M. Prados, Neuro Oncol 2016, 18, 557.
L. Sercombe, T. Veerati, F. Moheimani, S. Y. Wu, A. K. Sood, S. Hua, Front. Pharmacol. 2015, 6, 286.
a) G. R. Gunassekaran, S. M. Poongkavithai Vadevoo, M. C. Baek, B. Lee, Biomaterials 2021, 278, 121137;
b) L. Cheng, Y. Wang, L. Huang, Mol. Ther. 2017, 25, 1665;
c) H. Kim, S. Y. Wang, G. Kwak, Y. Yang, I. C. Kwon, S. H. Kim, Adv. Sci. 2019, 6, 1900513.
a) W. J. Goh, S. Zou, W. Y. Ong, F. Torta, A. F. Alexandra, R. M. Schiffelers, G. Storm, J. W. Wang, B. Czarny, G. Pastorin, Sci. Rep. 2017, 7, 14322;
b) S. C. Jang, O. Y. Kim, C. M. Yoon, D.‐S. Choi, T.‐Y. Roh, J. Park, J. Nilsson, J. Lötvall, Y.‐K. Kim, Y. S. Gho, ACS Nano 2013, 11, 7698.
K. R. Neupane, G. S. Ramon, B. Harvey, B. Chun, S. P. Aryal, A. A. Masud, J. R. McCorkle, J. M. Kolesar, P. M. Kekenes‐Huskey, C. I. Richards, Adv. Healthcare Mater. 2023, 12, 2301163.
B. T. Harvey, X. Fu, L. Li, K. R. Neupane, N. Anand, J. M. Kolesar, C. I. Richards, ACS Omega 2022, 7, 46222.
K. R. Neupane, J. R. McCorkle, T. J. Kopper, J. E. Lakes, S. P. Aryal, M. Abdullah, A. A. Snell, J. C. Gensel, J. Kolesar, C. I. Richards, ACS Omega 2021, 6, 3847.
Y.‐J. Li, J.‐Y. Wu, J. Liu, W. Xu, X. Qiu, S. Huang, X.‐B. Hu, D.‐X. Xiang, J. Nanobiotechnol. 2021, 19, 242.
F. H. Moonschi, A. M. Fox‐Loe, X. Fu, C. I. Richards, Bio‐Protocol 2018, 8, e2825.
a) X. Dong, J. Gao, C. Y. Zhang, C. Hayworth, M. Frank, Z. Wang, ACS Nano 2019, 13, 1272;
b) J. Gao, M. Lee, X. Dong, Z. Wang, Methods Mol. Biol. 2022, 2394, 575.
G. van Meer, D. R. Voelker, G. W. Feigenson, Nat. Rev. Mol. Cell Biol. 2008, 9, 112.
F. Wang, R. A. Cerione, M. A. Antonyak, STAR Protocols 2021, 2, 100295.
J. Jang, H. Jeong, E. Jang, E. Kim, Y. Yoon, S. Jang, H. S. Jeong, G. Jang, Front. Plant Sci. 2022, 13, 1064412.
B. Zhang, T. J. Kopper, X. Liu, Z. Cui, S. G. Van Lanen, J. C. Gensel, CNS Neurosci Ther. 2019, 25, 591.
a) L. D. Miteva, N. S. Stanilov, T. S. Deliysky, S. A. Stanilova, Tumour Biol. 2014, 35, 12655;
b) L. Liu, F. Zheng, Onco Targets Ther. 2016, 9, 6083.
T. Hourani, J. A. Holden, W. Li, J. C. Lenzo, S. Hadjigol, N. M. O'Brien‐Simpson, Front. Oncol. 2021, 11, 788365.
K. B. Long, G. L. Beatty, Oncoimmunology 2013, 2, e26860.
C. Dostert, M. Grusdat, E. Letellier, D. Brenner, Physiol. Rev. 2019, 99, 115.
M. Li, X. Sun, J. Zhao, L. Xia, J. Li, M. Xu, B. Wang, H. Guo, C. Yu, Y. Gao, H. Wu, X. Kong, Q. Xia, Cell. Mol. Immunol. 2020, 17, 753.
R. Tokunaga, W. Zhang, M. Naseem, A. Puccini, M. D. Berger, S. Soni, M. McSkane, H. Baba, H.‐J. Lenz, Cancer Treat. Rev. 2018, 63, 40.
E. Derlindati, A. D. Cas, B. Montanini, V. Spigoni, V. Curella, R. Aldigeri, D. Ardigò, I. Zavaroni, R. C. Bonadonna, PLoS One 2015, 10, e0119751.
A. Bateman, M.‐J. Martin, S. Orchard, R. Agivetova, E. H. Bowler‐Barnett, R. Britto, H. Bye‐A‐Jee, R. Coetzee, A. Cukura, A. D. Silva, P. Denny, T. Ebenezer, P. Garmiri, G. Georghiou, E. Hatton‐Ellis, A. Hussein, R. Ishtiaq, P. Jokinen, V. Joshi, D. Jyothi, R. Lopez, A. Luciani, Y. Lussi, A. MacDougall, F. Madeira, M. Mahmoudy, M. Menchi, A. Mishra, K. Moulang, C. S. Oliveira, et al., Nucleic Acids Res. 2021, 49, D480.
J. Ren, X. Han, H. Lohner, R. Liang, S. Liang, H. Wang, J. Immunol. 2021, 207, 268.
K. Boriachek, M. N. Islam, A. Möller, C. Salomon, N. T. Nguyen, M. S. A. Hossain, Y. Yamauchi, M. J. A. Shiddiky, Small 2018, 14, 1702153.
The UniProt Consortium, Nucleic Acids Res. 2021, 49, D480.